Check for updates

Clinical and biochemical characteristics for patients with polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes syndrome: a pilot observational study

Pei Li[1†], Ye Zhang[1†], Li-Min Luo[2†], Wen-Qing Wang[3], Jing Li[1], Yan Cheng[1], Xiao Dang[1], Yang Chen[4] and Wei Jiang[5*]

[1]Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China, [2]Department of Infectious Diseases, Air Force Hospital of Southern Theatre Command, Guangzhou, Guangdong, China, [3]Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China, [4]School of Basic Medicine, Fourth Military Medical University, Xi'an, Shaanxi, China, [5]Department of Nursing Affairs, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China

Background: Polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome is rare life-threatening condition associated with a clonal plasma cell neoplasm.

Objective: The aim of this study is to investigate the clinical and biochemical features in patients with POEMS syndrome before and post-therapy.

Methods: Characteristics of demographic information, underlying diseases, clinical manifestations, laboratory indicators, and imaging examination were retrospectively collected when diagnosed and post-therapy in the patients POEMS syndrome between 2018 and 2024.

Results: Nineteen newly-diagnosed, treatment-naïve patients with POEMS syndrome were enrolled. The diagnosis of POEMS syndrome was re-analyzed and matched the diagnostic criteria updated in 2023. All patients presented the symptoms of polyneuropathy and positive for M-protein. Most patients suffered with hyperpigmentation ($n = 18$), organomegaly ($n = 18$), elevated vascular endothelial growth factor (VEGF) ($n = 17$), extravascular volume overload ($n = 15$), sclerotic bone lesions ($n = 11$), and hypothyroidism ($n = 10$). Serum alanine aminotransferase, aspartate aminotransferase, total bilirubin, total protein, and albumin levels were down-regulated, while uric acid level was up-regulated in patients with POEMS syndrome. Reduced triiodothyronine, thyroxine, free triiodothyronine levels were negatively correlated with urea nitrogen, creatinine, and uric acid levels in patients with POEMS syndrome. VEGF level, which was negatively correlated with Ca^{2+} level ($r = -0.56$), was reduced in most patients with POEMS syndrome receiving bortezomib/ixazomib and lenalidomide/thalidomide therapy. Aspartate aminotransferase, total protein, and estimated glomerular filtration rate levels were increased, while creatinine and uric acid levels were reduced post-therapy in patients with POEMS syndrome.

Conclusion: Patients with POEMS syndrome had impaired liver and renal function, and effective therapy might partly repair the liver and renal dysfunction.

KEYWORDS

POEMS syndrome, clinical characteristics, biochemical indicators, diagnosis, therapy

Introduction

Polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome is rare life-threatening condition associated with a clonal plasma cell neoplasm (1). The pathogenesis of POEMS syndrome is not fully elucidated. It is well-accepted that vascular endothelial growth factor (VEGF), a cytokine that secreted by different cell types (including plasma cells, marcophages, platelets, and osteoblasts, etc.) and targeting endothelial cells, correlates best with disease activity (1–3). VEGF overexpression appeared to be an important contributory element in POEMS syndrome (4), and the early evaluation of VEGF in inflammatory polyneuropathy could reduce the misdiagnosis of POEMS syndrome (5). However, anti-VEGF therapy fails to achieve successful results in POEMS syndrome (6). Although POEMS syndrome is a rare multisystemic plasma cell proliferation disorder (4), not all patients presents all aspects of the diagnostic criteria and the acronym does not encompass all manifestations of this syndrome (1). The prevalence of POEMS syndrome was reported as 0.3 cases per 100,000 individuals based on the Japanese national survey in 2003 (7). Importantly, POEMS syndrome has increasingly received attention due to the improved diagnostic level and quality of health services in China (8, 9).

Clinicians always overlook or misdiagnose at the early stage of POEMS syndrome due to the chronic disorders and multisystemic involvements, leading to delay in treatment and poor clinical outcomes. Approximate 31.9% patients inappropriately treated with glucocorticoids before the confirmation of POEMS syndrome (8). POEMS syndrome can masquerades or co-afflicts with numerous clinical conditions, such as diabetic foot (10), quasi-moyamoya disease (11, 12), hydrocephalus (13), portal hypertension (14, 15), porto-sinusoidal vascular disorder (16), chronic diarrhea (17), systemic mastocytosis (18), and heart failure (19, 20). Thus, it is pivotal to understand the clinical manifestations and routine laboratory indicators for early recognition of POEMS syndrome. Although biochemical characteristics, especially liver and renal functions, are not included in the diagnostic criteria for POEMS syndrome, several observational studies and reports have indicated the potential relationship between POEMS syndrome and hepatic/kidney dysfunctions (21–24). The renal function can be monitored by the determination of creatinine. The estimated glomerular filtration rate (eGFR) is usually calculated from equations by using serum creatinine level, age, race, sex, and body weight (25, 26). Accordingly, a comprehensive analysis of biochemical features of POEMS syndrome is required. Thus, we collected clinical presentations and laboratory/imaging data to improve the understanding of POEMS syndrome.

Materials and methods

Ethics

This study protocol was approved by the Institutional Review Board of Tangdu Hospital (No. K202404-04). This study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The data were collected on July 2024. We used an anonymized database for all analyses, and all potentially identifying variables were removed.

Study subjects

The retrospective observational study included 19 patients with newly diagnosed POEMS syndrome between January 2018 and June 2024 in Tangdu Hospital. The diagnosis of POEMS syndrome was re-analyzed by Dr. Wen-Qing Wang, based on the updated criteria raised by Dispenzieri in 2023 (1). The mandatory major criteria are polyneuropathy (typically demyelinating) and monoclonal plasma cell-proliferative disorder (almost always λ). Three other major criteria are Castleman disease, sclerotic bone lesions, and VEGF elevation. Six minor criteria are organomegaly (splenomegaly, hepatomegaly, or lymphadenopathy), extravascular volume overload (edema, pleural effusion, or ascites), endocrinopathy (adrenal, thyroid, pituitary, gonadal, parathyroid, or pancreatic), skin changes (hyperpigmantation, hypertrichosis, glomeruloid hemangiomata, plethora, acrocyanosis, flushing, or white nails), papilledema, thrombocytosis/polycythemia. The diagnosis of POEMS syndrome was based on the presentation of both mandatory major criteria, one of the three other major criteria, and one of the six minor criteria (1). The diagnosis criteria for each studied patient with POEMS syndrome are shown in Table 1. All patients were treatment-naïve, and did not suffer with important organ dysfunction. Meanwhile, twenty-five age- and sex-matched healthy individuals were also included as the control group.

Data collection

Clinical data from identified cases were abstracted from the medical records, including demographic information, underlying diseases, clinical manifestations, laboratory indicators when diagnosed as POEMS syndrome. The representative results of physical examination and [18]fluorodeoxyglucose-positron emission tomography/computed tomoprahy (^{18}F-FDG PET/CT) scanning as well as the therapeutic strategies were also collected.

Statistical analyses

Statistical analyses were performed using SPSS Version 25.0 (IBM SPSS Software, Chicago, IL, USA). For categorical variables, data were presented as n (%). Fisher's exact test was used for comparison. Continuous variables following normal distribution were presented as mean ± standard deviation. Student's t-test was used for comparison between two groups. Paired t-test was used for comparison between patients before and post therapies. Continuous variables following skewed distribution were presented as median (interquartile range) [M (Q1, Q3)]. Mann-Whitney U-test was used for comparison between two groups. Wilcoxon matched pairs test was used for between patients before and post therapies. Spearman's rank-order correlation coefficient was used for determining the correlation between parameters for liver

TABLE 1 The diagnosis criteria each enrolled patients with POEMS syndrome.

No.	Age (years)	Sex	Mandatory major criteria		Other major criteria			Minor criteria					
			Polyneuropathy	M-protein	Castleman disease	Sclerotic bone lesions	VEGF elevation&	Organomegaly	Extravascular volume overload	Endocrinopathy	Skin changes	Papilledema	Thrombocytosis/polycythemia
1	38	F	Extremities numbness, electromyography: sensory-motor deficit	IgA (+) λ-LC (+)	–	–	1,335.6 pg/ml	Lymphadenopathy	Pericardial effusion	–	Hyperpigmentation	–	–
2	43	M	Extremities numbness, electromyography: sensory-motor deficit, demyelinating	IgG (+) λ-LC (+)	–	+	>800 pg/ml	Lymphadenopathy	–	Gonadal	Hyperpigmentation	+	–
3	39	M	Extremities numbness, electromyography: sensory-motor deficit, demyelinating	IgA (+) λ-LC (+)	–	+	550.2 pg/ml	Splenomegaly, lymphadenopathy	Pericardial and pleural effusion	–	Hyperpigmantation, hypertrichosis, white nails	–	–
4	71	F	Extremities numbness	IgA (+) λ-LC (+)	–	+	572.3 pg/ml	Splenomegaly, lymphadenopathy	Pleural effusion, ascites	Hypothyroidism	Hyperpigmantation	–	–
5	41	F	Extremities weakness, electromyography: sensory-motor deficit	+	–	–	828.2 pg/ml	Splenomegaly, lymphadenopathy	–	Hypothyroidism, panceratic	Hyperpigmantation, hypertrichosis, white nails	+	Platelets 572 × 10^9/L
6	34	F	Extremities weakness, numbness, electromyography: sensory-motor deficit	IgA (+) λ-LC (+)	–	–	536.6 pg/ml	Lymphadenopathy	Pericardial and pleural effusion	Hypothyroidism	–	+	–

(Continued)

TABLE 1 (Continued)

No.	Age (years)	Sex	Mandatory major criteria		Other major criteria			Minor criteria						
			Polyneuropathy	M-protein	Castleman disease	Sclerotic bone lesions	VEGF elevation$^{\&}$	Organomegaly	Extravascular volume overload	Endocrinopathy	Skin changes	Papilledema	Thrombocytosis/polycythemia
7	43	M	Extremities weakness, numbness, electromyography: sensory-motor deficit, demyelinating	IgG (+) λ-LC (+)	–	+	786.9 pg/ml	Lymphadenopathy	–	Hypothyroidism, panceratic	Hyperpigmantation	–	–
8	48	F	Extremities weakness, numbness	IgA (+) λ-LC (+)	–	+	252.0 pg/ml	Splenomegaly, hepatomegaly	Pericardial effusion, ascites	Gonadal	Hyperpigmantation	+	–
9	45	F	Extremities weakness, electromyography: sensory-motor deficit, demyelinating	IgA (+) λ-LC (+)	–	–	1.098.2 pg/ml	Splenomegaly, hepatomegaly	Edema, pericardial effusion, ascites	Hypothyroidism	Hyperpigmantation	–	–
10	60	F	Extremities numbness, electromyography: sensory-motor deficit, demyelinating	IgA (+) λ-LC (+)	–	+	17.25 pg/ml	Splenomegaly, hepatomegaly, lymphadenopathy	Edema, pericardial effusion, ascites	Hypothyroidism	Hyperpigmantation	–	–
11	47	M	Extremities numbness, neuropathic pain, electromyography: sensory-motor deficit	IgA (+) λ-LC (+)	–	+	Not determined	Splenomegaly, hepatomegaly, lymphadenopathy	Edema, pericardial effusion	Hypothyroidism, panceratic	Hyperpigmantation	–	–
12	36	M	Extremities weakness	IgA (+) λ-LC (+)	+	+	>800 pg/ml	Splenomegaly, hepatomegaly, lymphadenopathy	–	–	Hyperpigmantation	–	–
13	65	M	Extremities weakness, electromyography: sensory-motor deficit	IgA (+) λ-LC (+)	–	–	482.3 pg/ml	–	Edema, pericardial and pleural effusion, ascites	Hypothyroidism	Hyperpigmantation	–	–

(Continued)

TABLE 1 (Continued)

No.	Age (years)	Sex	Mandatory major criteria		Other major criteria			Minor criteria					
			Polyneuropathy	M-protein	Castleman disease	Sclerotic bone lesions	VEGF elevation[&]	Organomegaly	Extravascular volume overload	Endocrinopathy	Skin changes	Papilledema	Thrombocytosis/ polycythemia
14	49	F	Extremities weakness, electromyography: sensory-motor deficit, demyelinating	IgG (+) λ-LC (+)	–	+	1,061.2 pg/ml	Splenomegaly, hepatomegaly, lymphadenopathy	Pleural effusion, ascites	Hypothyroidism	Hyperpigmantation	–	–
15	52	M	Extremities weakness, numbness, electromyography: sensory-motor deficit, demyelinating	+	–	+	>1,600 pg/ml	Splenomegaly, hepatomegaly, lymphadenopathy, cardiomegaly	Edema, pericardial and pleural effusion, ascites	Hypoparathyroidism	Hyperpigmantation	–	–
16	50	M	Extremities numbness, electromyography: sensory-motor deficit, demyelinating	IgA (+) λ-LC (+)	–	–	>1,600 pg/ml	Splenomegaly, hepatomegaly, lymphadenopathy	Ascites	–	Hyperpigmantation	+	–
17	47	F	Extremities weakness, numbness, electromyography: sensory-motor deficit, demyelinating	IgG (+) λ-LC (+)	–	+	1,431.1 pg/ml	Splenomegaly, lymphadenopathy	Edema, pericardial and pleural effusion, ascites	Hypothyroidism	Hyperpigmantation	+	–
18	48	F	Extremities numbness, neuropathic pain, electromyography: sensory-motor deficit	IgG (+) κ-LC (+)	–	–	553.6 pg/ml	Cardiomegaly	Pericardial effusion	–	Hyperpigmantation	–	–
19	52	M	Extremities weakness, numbness, electromyography: sensory-motor deficit	IgG (+) λ-LC (+)	–	–	859.3 pg/ml	Splenomegaly, lymphadenopathy	Pleural effusion	–	Hyperpigmantation	–	–

F, female; M, male; λ-LC, λ-light chain; κ-LC, κ- light chain; VEGF, vascular endothelial growth factor.
[&]Normal range of VEGF: 0–142.2 pg/ml.

FIGURE 1
Representative manifestations of POEMS syndrome. **(A)** Skin changes including hyperpigmentation and white nails. ^{18}F–FDG PET/CT scanning revealed **(B)** diffused osteosclerosis of pelvis (green arrows), **(C)** splenomegaly and hepatomegaly, **(D)** axillary fossa lymphadenectasis (yellow arrows).

function and demographic or clinical index. A *P*-value < 0.05 was considered statistically significant.

Results

Baseline clinical and laboratory characteristics of patients with POEMS syndrome

All enrolled patients with POEMS syndrome matched diagnosis criteria updated in 2023 (Table 1). The first visit department was Neurology (initial symptoms: lower extremities weakness and numbness; $n = 9$), Infectious Diseases (initial symptoms: liver cirrhosis and ascites; $n = 3$), Nephrology (initial symptoms: edema; $n = 3$), Gastroenterology (initial symptoms: abdominal distension; $n = 2$), Rheumatology (initial symptoms: lower extremities numbness; $n = 1$), and Hematology (initial symptoms: lower extremities weakness; $n = 1$), respectively. All patients suffered with the symptoms of polyneuropathy. As previously reported, distal symmetric sensorimotor syndrome is the clinical presentation of polyneuropathy mostly frequently seen (27), which was found in all enrolled patients. Sensory, motor, or autonomic symptoms form the main focus depending on the type of nerve fiber involved (27). The sensory symptoms includes ① sensation of furriness and numbness, ② tingling, burning, and cold parasthesia, ③ burning pain, stinging, electric shock-like pain, ④ gait instability, falls (27). The main sensory symptoms of enrolled patients were extremities numbness ($n = 14$) and neuropathic pain ($n = 2$). The motor symptoms include ① weakness, muscle loss, ② muscle

carmps, fasciculations (27). The main sensory symptom of enrolled patients was weakness ($n = 11$). Autonomic symptoms were dry skin, body hair loss, sensation of glare, bladder dysfunction, diarrhea, rapid heartbeat, gastrointestinal symptoms, urogenital symptoms (e.g., impaired micturitionerectile dysfunction) (27). However, no enrolled patients had obvious autonomic symptoms. Meanwhile, electromyography was performed in 16 patients, and the main presentations were sensory-motor deficit ($n = 16$) and demyelinating ($n = 9$). Furthermore, all patients were had monoclonal plasma cell-proliferative disorder, which presented as positive for serum M-protein. Two patients were positive for M-protein in serum protein electrophoresis, while 17 patients had were positive for M-protein in immunofixation electrophoresis, including 11 cases of IgA type λ-light chain (λ-LC), five cases of IgG type λ-LC, and one case of IgG type κ-LC. One case was confirmed as Castleman disease via lymph node biopsy. Eleven cases showed sclerotic bone lesions based on computed tomography (CT), magnetic resonance imaging (MRI), or ^{18}F-FDG PET/CT scanning. Eighteen patients received serum VEGF quantification, and 17 of them had elevated serum VEGF level (>142.2 pg/ml). Organomegaly was found in 18 patients, which presented as lymphadenopathy ($n = 15$), splenomegaly ($n = 13$), hepatomegaly ($n = 7$), and cardiomegaly ($n = 2$). Extravascular volume overload was found in 15 patients, which presented as pericardial effusion ($n = 10$), pleural effusion ($n = 8$), ascites ($n = 8$), and edema ($n = 5$). The main presentation of endocrinopathy was hypothyroidism ($n = 10$), while the main presentation of skin changes was hyperpigmentation ($n = 18$) as the representative manifestation in Figure 1A. However, only one patient revealed thrombocytosis (platelets count 572×10^9/L), and no patients manifested as polycythemia. Furthermore, six patients were also diagnosed as plasmacytoma, and two of them were multiple myeloma. Five patients had underlying chronic diseases, including chronic glomerulonephritis and liver cirrhosis. Importantly, four patients received ^{18}F-FDG PET/CT scanning. The main findings in ^{18}F-FDG PET-CT scanning were diffused osteosclerosis of pelvis (Figure 1B), splenomegaly and hepatomegaly (Figure 1C), axillary fossa lymphadenectasis (Figure 1D).

The baseline characteristics of enrolled subjects are shown in Table 2. There was no significant difference in white blood cell (WBC) count between patients with POEMS syndrome and controls ($P = 0.547$). Patients with POEMS syndrome had elevated platelet count ($P = 0.002$), while had reduced levels of red blood cell (RBC) count ($P = 0.008$) and hemoglobin ($P < 0.001$) compared with controls. Importantly, patients with POEMS syndrome had significant reduced levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (T-BIL), total protein, and albumin compared with controls (all $P < 0.05$). Although there were no remarkable differences in urea nitrogen, creatinine, or eGFR between patients with POEMS syndrome and controls ($P > 0.05$), uric acid level was robustly elevated in patients with POEMS syndrome ($P = 0.003$). Patients with POEMS syndrome had significantly down-regulated Na^+ and Ca^{2+} levels ($P < 0.001$) and up-regulated blood glucose level ($P = 0.007$). Patients with POEMS syndrome had reduced triiodothyronine (T3), thyroxine (T4), free triiodothyronine (FT3), and free thyroxine (FT4) levels and elevated thyroid stimulating

TABLE 2 Baseline characteristics of enrolled subjects.

	POEMS syndrome	Controls	P-value
Case (n)	19	25	–
Age (years)	47.89 ± 9.57	45.24 ± 5.64	0.256
Male gender (n, %)	9 (47%)	13 (52%)	0.761
Female gender (n, %)	10 (53%)	12 (48%)	0.761
Blood routine test			
WBC ($\times 10^9$/L)	5.94 ± 1.99	5.65 ± 1.21	0.547
Platelet ($\times 10^9$/L)	318.9 ± 97.72	241.6 ± 53.87	0.002
RBC ($\times 10^{12}$/L)	4.35 ± 0.62	4.78 ± 0.38	0.008
Hemoglobin (g/L)	127.1 ± 13.41	145.8 ± 14.70	<0.001
Liver function			
ALT (U/L)	11 (6, 18)	16 (11, 27)	0.016
AST (U/L)	12 (10, 16)	21 (18, 24)	<0.001
T-BIL (μmol/L)	11.26 ± 4.03	17.66 ± 5.85	<0.001
Total protein (g/L)	61.25 ± 4.85	72.98 ± 4.15	<0.001
Albumin (g/L)	35.11 ± 4.01	45.42 ± 2.89	<0.001
Globulin (g/L)	26.13 ± 5.02	27.56 ± 3.41	0.269
Renal function			
Urea nitrogen (mmol/L)	5.30 (4.21, 11.80)	5.40 (4.10, 7.05)	0.507
Creatinine (μmol/L)	66.00 (53.20, 100.0)	70.00 (54.00, 80.00)	0.981
Uric acid (μmol/L)	428.4 ± 142.2	327.9 ± 65.29	0.003
eGFR (ml/min/1.73 m²)	115.0 (58.84, 147.2)	101.2 (93.01, 117.0)	0.840
Electrolyte			
K^+ (mmol/L)	4.46 ± 0.87	4.37 ± 0.25	0.622
Na^+ (mmol/L)	138.1 ± 3.05	140.9 ± 1.70	<0.001
Cl^- (mmol/L)	105.1 ± 2.77	104.2 ± 1.72	0.189
Ca^{2+} (mmol/L)	2.12 ± 0.14	2.38 ± 0.10	<0.001
Blood glucose (mmol/L)	5.89 ± 1.36	5.07 ± 0.44	0.007
Thyroid function			
T3 (nmol/L)	1.03 (0.69, 1.60)	1.79 (1.58, 2.08)	<0.001
T4 (nmol/L)	75.05 ± 22.25	102.4 ± 15.63	<0.001
FT3 (pmol/L)	2.98 ± 1.31	4.82 ± 0.82	<0.001
FT4 (pmol/L)	11.92 ± 3.39	18.03 ± 2.32	<0.001
TSH (uIU/mL)	7.71 (4.98, 12.56)	1.62 (1.22, 3.13)	<0.001
Immunoglobulin (Ig) and complement (C)			
IgG (g/L)	12.00 (9.27, 13.70)	N.D.	–

(Continued)

TABLE 2 (Continued)

	POEMS syndrome	Controls	P-value
IgA (g/L)	3.57 (1.85, 7.14)	N.D.	–
IgM (g/L)	0.88 (0.46, 1.53)	N.D.	–
κ-LC (g/L)	2.37 (1.99, 3.05)	N.D.	–
λ-LC (g/L)	2.25 (1.79, 2.50)	N.D.	–
κ/λ	1.07 (0.95, 1.38)	N.D.	–
C3 split product (g/L)	0.92 ± 0.16	N.D.	–
C4 (g/L)	0.24 ± 0.06	N.D.	–
C1 inhibitor (g/L)	0.30 ± 0.08	N.D.	–

WBC, white blood cells; RBC, red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; T-BIL, total bilirubin; eGFR, estimated glomerular filtration rate; T3, triiodothyronine; T4, thyroxine; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid stimulating hormone; κ-LC, κ-light chain; λ-LC, λ- light chain; N.D., not determined.

hormone (TSH) level due to the diagnosis of hypothyroidism in ten patients ($P < 0.001$). The levels of immunoglobulin and complement were only assessed in patients with POEMS syndrome, and λ-light chain (λ-LC) level was slightly higher than the upper limit of normal (normal range: 0.9–2.1 g/L).

Correlations between clinical indexes in patients with POEMS syndrome

The correlations between clinical indexes in patients with POEMS syndrome were analyzed, and the results are shown in Table 3. There were several common correlations between clinical indicators. Serum K^+ level was positively correlated with urea nitrogen, creatinine, and uric acid levels, while negatively correlated with eGFR (all $P < 0.05$), because potassium are mainly excreted through urine. Serum κ-LC level was positively correlated with levels of IgG ($r = 0.60$, $P = 0.007$) and IgM ($r = 0.49$, $P = 0.032$), while serum λ-LC level was positively correlated with IgA level ($r = 0.70$, $P < 0.001$) because most of the patients (58%, 11/19) had IgA type λ-LC M-protein based on immunofixation electrophoresis analysis. Importantly, serum T3, T4, and FT3 levels were positively correlated with hemoglobin and eGFR, while negatively correlated with urea nitrogen, creatinine, and uric acid levels (all $P < 0.05$), indicating the correlation between reduced thyroid function and impaired renal function. Furthermore, serum VEGF level was negatively correlated with Ca^{2+} level in patients with POEMS syndrome ($r = -0.56$, $P = 0.016$).

Changes of laboratory indexes in response to therapy in patients with POEMS syndrome

Fourteen patients with POEMS syndrome received bortezomib/ixazomib and lenalidomide/thalidomide therapy,

and two of them received hematopoietic stem cell transplantation. The patients were followed-up at least 6 months post-therapy. The symptoms of polyneuropathy (especially distal symmetric sensorimotor syndrome) as well as the hyperpigmentation of the skin were ameliorated in response to therapy. VEGF level was reduced in response to therapy in eleven patients, but three patients had increased serum VEGF level post-therapy. Routine tests, including blood routine test, liver and renal function, and electrolytes, were performed in those fourteen patients before and post therapy. Platelet count was robustly down-regulated to the normal range in response to therapy ($P = 0.001$, Table 4). However, there were no significant differences in WBC, RBC, or hemoglobin level between baseline and post-therapy (all $P > 0.05$, Table 4). AST and total protein levels were increased in response to therapy (all $P < 0.05$, Table 4). Meanwhile, ALT and albumin levels were also increased post-therapy, however, this difference just failed to achieve statistical significance ($P = 0.090$ and $P = 0.069$, Table 4). Serum creatinine and uric acid levels were reduced, while eGFR level was increased post-therapy (all $P < 0.05$, Table 4). There were no remarkable differences in urea nitrogen or electrolytes levels between baseline and post-therapy (all $P > 0.05$, Table 4). Taken together, effective therapeutic strategies normalized the platelet count, AST and total protein level, as well as the main kidney functions, especially eGFR.

Discussion

In this retrospective study, we reported the clinical characteristics of patients with POEMS syndrome in a tertiary-care hospital in Xi'an, China. We found that the most common symptoms of initial symptoms were lower extremities weakness and numbness (58%, 11/19), followed by the symptoms of extravascular volume overload (32%, 6/19). There were several abnormal routine laboratory indexes in newly diagnosed POEMS syndromes, including the up-regulation of platelet count, uric acid, and λ-LC level as well as the down-regulation of RBC count, hemoglobin, total protein, albumin, Ca^{2+}, and thyroid hormone levels. Furthermore, although there were statistical differences in ALT, AST, T-BIL, Na^+, and blood glucose levels between patients with POEMS syndrome and healthy individuals, these indicators were still within the normal range. Therefore, the clinical manifestations of POEMS syndrome were complex and diverse, with significant individual differences.

The diagnosis of POEMS syndrome was based on the two mandatory major criteria, three major criteria, and six minor features (1, 28, 29). Except for the presentation of polyneuropathy and positive for M-protein in all 19 patients, we found that elevated VEGF (17 cases), organomegaly (18 cases), and hyperpigmentation (18 cases) were the most common criteria for diagnosis of POEMS syndrome. We also found that elevated VEGF was negatively correlated with serum Ca^{2+} level, which was reduced in patients with POEMS syndrome. This was consistent with the physiological finding that VEGF could stimulate calcium ion flux in endothelial cells (30), mediating the elevation of intracellular release and extracellular entry of calcium (31, 32). In turn, the intracellular calcium could also regulated VEGF secretion in human adipocytes. The serum Ca^{2+} level indicated

TABLE 3 The correlations between clinical indexes in patients with POEMS syndrome.

	Blood routine test				Liver function						Renal function				Electrolyte				BG	Thyroid function					Immunoglobulin (Ig) and complement (C)								VEGF
	WBC	PLT	RBC	HGB	ALT	AST	T-BIL	TP	ALB	GLO	BUN	Cr	UA	eGFR	K+	Na+	Cl−	Ca2+	BG	T3	T4	FT3	FT4	TSH	IgG	IgA	IgM	κ-LC	λ-LC	C3SP	C4	C1I	VEGF
WBC		0.26	0.31	0.14	0.24	0.42	−0.35	0.08	0.14	−0.03	0.07	015	−0.22	−0.01	0.04	0.42	0.05	0.02	0.29	0.16	0.03	0.01	−0.08	−0.11	−0.24	−0.07	0.04	0.22	−0.45	0.40	0.27	0.40	0.03
PLT			0.01	−0.09	−0.10	−0.10	−0.16	**−0.64#**	−0.27	−0.41	−0.10	−0.02	−0.16	0.13	−0.30	0.23	−0.01	−0.16	0.25	0.02	0.22	0.08	0.04	−0.24	−0.20	−0.02	−0.03	−0.04	−0.23	0.24	−0.01	0.13	0.07
RBC				**0.84#**	−0.05	0.20	−0.19	0.25	0.37	−0.05	0.05	−0.18	−0.12	0.36	0.12	0.11	**−0.49#**	0.08	**0.47#**	**0.60#**	0.44	0.44	0.34	−0.22	−0.12	−0.13	−0.24	−0.01	−0.24	0.40	0.37	0.25	0.16
HGB					−0.06	0.08	0.18	0.23	0.39	−0.10	−0.10	−0.30	−0.23	0.46	−0.03	0.25	−0.43	0.28	0.36	**0.76#**	**0.59#**	**0.62#**	0.45	0.01	−0.01	−0.22	−0.12	−0.10	−0.16	0.33	0.32	−0.17	0.03
ALT						**0.74#**	−0.00	0.09	−0.02	0.30	−0.37	0.20	0.17	−0.20	0.22	0.04	−0.27	0.20	−0.03	−0.35	**−0.52#**	−0.46	−0.39	0.19	−0.18	−0.00	−0.03	−0.06	−0.14	0.14	−0.06	0.11	−0.21
AST							−0.33	0.31	0.02	0.38	0.33	0.25	−0.01	−0.13	0.30	0.09	−0.18	0.22	−0.13	−0.17	−0.34	−0.29	−0.30	0.20	−0.28	0.30	0.22	0.30	−0.13	0.08	−0.11	0.41	−0.38
T−BIL								0.02	−0.11	0.11	−0.29	−0.20	−0.14	0.07	−0.38	0.01	−0.16	0.09	−0.14	0.24	0.11	−0.05	0.05	**0.65#**	0.31	−0.28	−0.13	−0.37	0.18	0.26	0.27	−0.40	0.07
TP									0.37	**0.67#**	−0.20	−0.27	−0.25	0.23	−0.08	0.02	−0.31	0.20	−0.19	0.26	0.19	0.02	0.06	0.48	0.37	0.06	0.13	0.39	0.23	−0.01	0.15	−0.23	−0.11
ALB										−0.44	−0.01	−0.17	−0.20	0.27	0.23	0.22	0.05	**0.48#**	0.18	0.40	0.27	0.44	0.27	−0.26	−0.31	−0.19	0.25	0.07	**−0.48#**	0.07	0.14	−0.17	0.02
GLO											−0.11	−0.04	−0.09	−0.08	−0.26	−0.15	−0.34	−0.19	−0.33	−0.09	−0.03	−0.34	−0.17	**0.73#**	**0.61#**	0.22	−0.07	0.32	**0.60#**	−0.06	0.01	−0.06	−0.02
BUN												**0.84#**	**0.82#**	**−0.72#**	**0.82#**	−0.14	0.01	0.07	−0.02	**−0.61#**	**−0.68#**	**−0.64#**	−0.40	0.01	**−0.52#**	0.36	−0.18	−0.21	0.06	−0.04	−0.06	**0.55#**	−0.11
Cr													**0.72#**	**−0.68#**	**0.78#**	−0.06	0.23	−0.06	−0.32	**−0.67#**	**−0.67#**	**−0.60#**	−0.44	0.19	−0.37	0.35	−0.16	−0.08	0.10	0.10	0.10	**0.75#**	−0.15
UA														**−0.95#**	**0.60#**	**−0.57#**	−0.02	−0.28	0.05	**−0.66#**	**−0.66#**	**−0.72#**	−0.49	−0.00	−0.43	**0.50#**	−0.36	−0.33	0.27	−0.18	0.03	0.44	0.01
eGFR															**−0.63#**	0.17	−0.23	0.18	0.40	**0.74#**	**0.66#**	**0.80#**	**0.60#**	−0.30	0.23	**−0.31**	0.21	0.12	−0.25	−0.12	−0.16	**−0.67#**	0.11
K+																−0.43	0.29	0.05	0.22	0.11	−0.30	−0.29	−0.04	−0.02	−0.32	0.10	−0.15	−0.02	−0.19	−0.07	−0.06	0.48	−0.11
Na+																	0.29	−0.01	−0.06	0.28	0.21	0.30	−0.19	0.26	0.18	−0.25	**0.68#**	0.38	−0.22	−0.08	−0.11	−0.30	0.12
Cl−																		0.03	−0.09	−0.34	−0.20	−0.13	−0.13	−0.06	0.10	−0.23	0.45	0.26	−0.22	**−0.55#**	**−0.49#**	−0.04	−0.04
Ca2+																			0.17	−0.04	0.39	0.37	**0.54#**	0.02	−0.19	−0.10	0.13	−0.01	−0.29	007	0.14	−0.16	**−0.56#**
BG																				0.32	0.17	0.33	0.40	**−0.60#**	−0.24	−0.25	−0.39	−0.20	−0.43	0.18	0.31	0.25	0.11
T3																					**0.78#**	**0.94#**	**0.58#**	−0.24	0.14	−0.32	0.27	0.09	−0.27	0.38	0.45	−0.40	0.47
T4																						**0.77#**	**0.83#**	−0.02	0.26	−0.51	0.23	0.25	−0.29	0.27	0.35	−0.19	0.20
FT3																							**0.72#**	−0.38	−0.04	−0.47	0.15	−0.02	−0.36	0.26	0.33	−0.15	0.17
FT4																								−0.31	−0.04	**−0.54#**	−0.11	−0.15	−0.38	−0.25	0.23	−0.07	0.02
TSH																									0.31	0.42	0.18	0.19	**0.69#**	0.16	0.10	−0.01	−0.28
IgG																										−0.32	0.18	**0.60#**	0.34	−0.27	−0.08	−0.43	0.25
IgA																											−0.12	−0.10	**0.70#**	0.05	0.02	0.36	−0.25
IgM																												**0.49#**	−0.09	−0.46	−0.33	−0.26	0.02
κ-LC																													0.02	−0.36	−0.07	−0.18	0.06
λ-LC																														−0.15	−0.12	−0.08	−0.09
C3SP																															**0.66#**	0.28	0.08
C4																																0.33	0.16
C1I																																	−0.17
VEGF																																	

WBC, white blood cells; PLT, platelets; RBC, red blood cells; HGB, hemoglobin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; T-BIL, total bilirubin; TP, total protein; ALB, albumin; GLO, globulin; BUN, urea nitrogen; Cr, creatinine; UA, uric acid; eGFR, estimated glomerular filtration rate; BG, blood glucose; T3, triiodothyronine; T4, thyroxine; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid stimulating hormone; κ-LC, κ-light chain; λ-LC, λ- light chain; C3SP, C3 split product; C1I, C1 inhibitor.
#P < 0.05.
The bold and underline values with # indicate statistical correlations with P value less than 0.05.

TABLE 4 Clinical indexes in patients with POEMS syndrome in response to therapy (n = 14).

	Baseline	Post-therapy	P-value
Blood routine test			
WBC ($\times 10^9$/L)	6.36 ± 1.95	6.07 ± 3.23	0.748
Platelet ($\times 10^9$/L)	328.0 ± 108.5	211.3 ± 121.3	0.001
RBC ($\times 10^{12}$/L)	4.24 ± 0.59	4.22 ± 0.89	0.951
Hemoglobin (g/L)	124.1 ± 13.57	123.7 ± 29.44	0.955
Liver function			
ALT (U/L)	11 (5, 18)	16 (12, 29)	0.090
AST (U/L)	12 (9, 16)	18 (13, 24)	0.006
T-BIL (μmol/L)	11.42 ± 4.50	16.95 ± 9.78	0.029
Total protein (g/L)	61.35 ± 4.38	65.40 ± 10.20	0.145
Albumin (g/L)	34.97 ± 3.89	38.98 ± 6.66	0.069
Globulin (g/L)	26.36 ± 5.14	26.44 ± 7.35	0.961
Renal function			
Urea nitrogen (mmol/L)	5.10 (4.21, 12.43)	6.25 (4.60, 9.77)	0.903
Creatinine (μmol/L)	68.50 (57.40, 103.8)	62.00 (51.25, 72.60)	0.030
Uric acid (μmol/L)	424.6 ± 134.7	312.1 ± 140.0	0.026
eGFR (ml/min/1.73 m²)	88.18 (57.77, 134.2)	114.3 (75.26, 157.6)	0.027
Electrolyte			
K^+ (mmol/L)	4.46 ± 1.16	4.16 ± 0.43	0.366
Na^+ (mmol/L)	138.7 ± 3.84	139.2 ± 4.77	0.746
Cl^- (mmol/L)	106.1 ± 2.61	105.1 ± 3.62	0.483
Ca^{2+} (mmol/L)	2.05 ± 0.14	2.17 ± 0.26	0.207

WBC, white blood cells; RBC, red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; T-BIL, total bilirubin; eGFR, estimated glomerular filtration rate.

the extracellular calcium, which might reflect the elevation of intracellular calcium, resulting in the elevation of VEGF and vascular permeability (32, 33). Thus, VEGF calcium signaling in endothelial cells (33) might contribute to the pathogenesis and disease progression of POEMS syndrome. Moreover, ^{18}F-FDG PET/CT is a useful tool for diagnosis and evaluation of patients with POEMS syndrome by providing the evidence of bone lesions, liver or spleen enlargement, lymphadenopathy, and cavity effusion (34). Four patients received ^{18}F-FDG PET/CT scanning, and the systemic findings were found in these patients, including the osteosclerosis (normometabolic bone changes), lymphadenopathy, hepatomegaly, and splenomegaly. Finally, although thrombocytosis/polycythemia has been involved in the updated diagnostic criteria of six minor features, we found slightly elevation of platelet count and only one patient match the diagnosis

of thrombocytosis (platelet count > 450×10^9/L). However, the mean hemoglobin level was low (127.1 g/L) and nine patients (47%) suffered with mild anemia. This was consistent with the report on consecutive Chinese cohort, showing that 26% patients had anemia (35). In our opinion, impaired renal function and difference in studied race might contribute to the anemia, which were still needed for further investigation.

The liver and renal function was not involved in the diagnostic criteria for POEMS syndrome, but these indicators were most commonly used in clinical practice for evaluation the status of patients. It was well-accepted that low serum albumin and reduced eGFR was poor prognostic risk factor for POEMS syndrome (1, 21, 28, 29). Herein, we found several abnormal indicators corresponding to liver and renal function in POEMS syndrome. Although ALT, AST, and T-BIL levels were within the normal range, these indicators were robustly down-regulated compared with healthy individuals. Furthermore, effective risk-adapted therapy increased the ALT, AST, and T-BIL levels. However, ALT, AST, and T-BIL levels did not strongly correlate with other clinical indicators in patients with POEMS syndrome. The elevations of aminotransferases reflected the hepatocytes damage and liver toxicity in several disease conditions. However, even the three patients with liver cirrhosis had very low levels of ALT (11, 14, and 20 U/L), AST (12, 13, and 14 U/L), and T-BIL (15.3, 7.6, and 9.4 μmol/L). The cause of decreased blood aminotransferase activity included drug-induced and metabolic categories (36). On the one hand, several patients had underlying diseases, but the administration of drugs did not contain the agents causing decreases in aminotransferase activity, such as delapril hydrochloride, izoniazid, cefazolin, canavanine, or oxodipine (36). On the other hand, metabolic factors, including severe weight loss, anorexia, vitamin B6 or zinc deficiency, also contributed to ALT and AST reduction (36). We did not assess the vitamin B6 or zinc level in patients with POEMS syndrome, but we still assumed that metabolic factors might play essential roles in decreased ALT, AST, and T-BIL levels in POEMS syndrome. Furthermore, Kourelis et al. indicated that albumin > 32 g/L was one of the important factors which were associated with superior overall survival of POEMS syndrome (21). We found that albumin level was reduced, and effective therapy increased the albumin level in patients with POEMS syndrome. Moreover, serum λ-LC was negatively correlated with albumin and positively correlated with globulin in patients with POEMS syndrome. Therefore, the quantification of λ-LC might also be associated with disease progression and outcomes of POEMS syndrome.

Renal impairment was a common complication of POEMS syndrome, and might be independently associated with ascites (37). In the current study, we found that eight patients (42%) with POEMS syndrome had reduced eGFR level (<90 ml/min/1.73 m²), including five moderate impairment (eGFR 30–59 ml/min/1.73 m²) and three severe dysfunction (eGFR < 30 ml/min/1.73 m²), which was consistent with the previous findings (37). However, the median level of eGFR was comparable with healthy individuals. Meanwhile, uric acid level was increased in POEMS syndrome. Importantly, effective therapy reversed the renal impairment, which presented as down-regulation of creatinine and uric acid as well as up-regulation of eGFR. Importantly, the impaired renal function seemed to be strongly associated with

hypothyroidism in POEMS syndrome. Previous studies revealed that subclinical hypothyroidism independently correlated with poor renal outcomes in patients with chronic kidney disease (38), and levothyroxine replacement therapy improved renal function in hypothyroidism patients (39). There might be a complex interaction between thyroid hormone and renal function. Although the several patients with POEMS syndrome complicated received levothyroxine replacement administration, they were not followed-up for thyroid function. Thus, we could not analyze the dynamic association between renal and thyroid function in POEMS syndrome.

There were several limitations in this study. Firstly, due to the very low incidence of POEMS syndrome and limited sample size, the expanded sample size through multi-center collaboration should be performed to strengthen the validity of the current conclusions. Secondly, we only tracked changes within 6 months post-treatment, missing long-term prognosis and outcomes. This was due to the fact that most patients were enrolled between the year 2023 and 2024. Extending the follow-up period would provide more comprehensive insights into treatment efficacy and quality of life. Thirdly, although we found the correlation between VEGF elevation and calcium signaling, further experimental studies exploring the pathophysiology of POEMS syndrome, leading to the in-depth investigation into the underlying mechanisms. Precise medication and deep learning might contribute to POEMS syndrome pathogenesis (40).

In summary, several patients with POEMS syndrome had impaired liver and renal function, and effective therapy might partly repair the liver and renal dysfunction. It is important for early diagnosis of POEMS syndrome, especially for general and neurological physicians. For those patients who suffered with polyneuropathy, the common and important laboratory indicators (blood routine test, liver and renal functions, electrolyte, thyroid function, etc.) should be monitors for early recognition of POEMS syndrome.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by the Institutional Review Board of Tangdu Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The Ethics Committee/Institutional Review Board waived the requirement of written informed consent for participation from the participants or the participants' legal guardians/next of kin due to the retrospective nature of the study.

Author contributions

PL: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation,

Writing – original draft. YZ: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft. L-ML: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – original draft. W-QW: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – review & editing. JL: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – review & editing. YCheng: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – review & editing. XD: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – review & editing. YChen: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – review & editing. WJ: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft.

Funding

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

YZ is the Associate Editor for Frontiers in Cellular and Microbiology Infection, section Clinical Microbiology. This had no impact on the peer review process and the final decision.

Generative AI statement

The author(s) declare that no Gen AI was used in the creation of this manuscript.

Publisher's note

References

1. Dispenzieri A, POEMS. syndrome: update on diagnosis, risk-stratification, and management. *Am J Hematol.* (2023) 98:1934–50. doi: 10.1002/ajh.27081

2. D'souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. *Blood.* (2011) 118:4663–5. doi: 10.1182/blood-2011-06-362392

3. Misawa S, Sato Y, Katayama K, Hanaoka H, Sawai S, Beppu M, et al. Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study. *BMJ Open.* (2015) 5:e009157. doi: 10.1136/bmjopen-2015-009157

4. Ali T, Qazilbash MH. POEMS syndrome: a multisystem clonal disorder. *Eur J Haematol.* (2021) 106:14–8. doi: 10.1111/ejh.13514

5. Marsh ES, Keddie S, Terris-Presholt F, D'sa S, Lunn MP. Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs. *J Neurol Neurosurg Psychiatry.* (2021) 92:172–76. doi: 10.1136/jnnp-2020-324012

6. Kanai K, Kuwabara S, Misawa S, Hattori T. Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome. *Intern Med.* (2007) 46:311–3. doi: 10.2169/internalmedicine.46.6246

7. Suichi T, Misawa S, Beppu M, Takahashi S, Sekiguchi Y, Shibuya K, et al. Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey. *Neurology.* (2019) 93:e975–83. doi: 10.1212/WNL.0000000000008062

8. Yu YY, Gao XM, Zhao H, Cai H, Feng J, Zhang L, et al. Treatment and outcomes of POEMS syndrome: changes in the past 20 years. *Blood Cancer J.* (2021) 11:145. doi: 10.1038/s41408-021-00540-1

9. Cui RT, Huang XS, Shi Q, Tian CL, Liu JX, Pu CQ, et al. (polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes) syndrome in China. *Intern Med J.* (2011) 41:481–5. doi: 10.1111/j.1445-5994.2010.02172.x

10. Zhou GX, Xiao L, Bi YM, Yang F, Yang CZ, Zhang D. Case report: POEMS syndrome masquerades as diabetic foot. *Front Neurol.* (2023) 14:1336382. doi: 10.3389/fneur.2023.1336382

11. Satma JN, Moradi I, Khachik L, Saad G, Gonzalez C. Intersecting pathologies: a case report on the co-presentation of Quasi-Moyamoya Disease and polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes (POEMS) syndrome. *Cureus.* (2024) 16:e65934. doi: 10.7759/cureus.65934

12. Kubota Y, Hanaoka Y, Koyama JI, Takahashi Y, Katoh N, Iwaya M, et al. Surgical revascularization for quasi-moyamoya disease associated with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome: a case report and literature review. *Nagoya J Med Sci.* (2023) 85:141–49.

13. Rodriguez-Dominguez V, Hernandez-Garcia BJ, Abenza-Abildua MJ. Hydrocephalus associated with POEMS syndrome. *Med Clin.* (2024) 163:212–13. doi: 10.1016/j.medcle.2024.02.012

14. Xu X, Jing C, Zhu T, Jiang M, Fu Y, Xie F, et al. Case report: POEMS syndrome with portal hypertension. *Front Med.* (2024) 11:1373397. doi: 10.3389/fmed.2024.1373397

15. Chen Y, Lin J, Jiang X, Zhou Q, Zhang H. A POEMS syndrome patient with idiopathic non-cirrhotic portal hypertension received the transjugular intrahepatic portosystemic shunt: a case report and literature review. *Niger J Clin Pract.* (2022) 25:1939–44. doi: 10.4103/njcp.njcp_360_22

16. Ferronato M, De Molo C, Bakken SM, Leoni FG, Vizioli L, Di Donato R, et al. Porto-sinusoidal vascular disorder, report of a novel association with POEMS syndrome. Future challenge for the hepatologist. *Clin Res Hepatol Gastroenterol.* (2023) 47:102126. doi: 10.1016/j.clinre.2023.102126

17. Bhattacharjee S, Siyad I, Maramattom BV. Chronic diarrhea - The poetic masquerade. *J Postgrad Med.* (2022) 68:239–42. doi: 10.4103/jpgm.jpgm_1169_21

18. Hou Y, Jiang S, Zhang L, Wang Y, Zhang L, Bao H, et al. A case of systemic mastocytosis mimicking POEMS syndrome: a case report. *Medicine.* (2022) 101:e28651. doi: 10.1097/MD.0000000000028651

19. Abdelahad M, Pearson R, Mauri B, Fenton K, Savu C. Heart failure with cardiogenic shock as a manifestation of untreated POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome. *Cureus.* (2021) 13:e18046. doi: 10.7759/cureus.18046

20. Hagiwara G, Arahata M, Hosokawa K, Shimojima M, Nakao S. Congestive heart failure associated with POEMS syndrome that was adequately distinguished from cardiac amyloidosis: a case report and literature review. *Ann Transl Med.* (2021) 9:1266. doi: 10.21037/atm-21-1071

21. Kourelis TV, Buadi FK, Kumar SK, Gertz MA, Lacy MQ, Dingli D, et al. Long-term outcome of patients with POEMS syndrome: an update of the Mayo Clinic experience. *Am J Hematol.* (2016) 91:585–9. doi: 10.1002/ajh.24356

22. Rees DO, Thomas DH, Parry-Jones N, Roberts G. A relapse of POEMS syndrome presenting as acute kidney injury. *BMJ Case Rep.* (2019) 12:228894. doi: 10.1136/bcr-2018-228894

23. Rekhtina I, Stolyarevich E, Zakharova E, Khyshova V, Mendeleeva L. A case of POEMS syndrome with severe kidney damage: lessons for the clinical nephrologist. *J Nephrol.* (2022) 35:2135–38. doi: 10.1007/s40620-022-01379-w

24. Yonemoto S, Ueda S, Oka K, Fujii N, Matsunaga H, Okuno A, et al. Renal biopsy is a helpful tool for the diagnosis of POEMS syndrome. *Int J Hematol.* (2012) 95:595–6. doi: 10.1007/s12185-012-1085-y

25. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function–measured and estimated glomerular filtration rate. *N Engl J Med.* (2006) 354:2473–83. doi: 10.1056/NEJMra054415

26. Pottel H, Delanaye P, Cavalier E. Exploring renal function assessment: creatinine, cystatin C, and estimated glomerular filtration rate focused on the European Kidney Function Consortium equation. *Ann Lab Med.* (2024) 44:135–43. doi: 10.3343/alm.2023.0237

27. Sommer C, Geber C, Young P, Forst R, Birklein F, Schoser B. Polyneuropathies. *Dtsch Arztebl Int.* (2018) 115:83–90. doi: 10.3238/arztebl.2018.0083

28. Dispenzieri A. POEMS Syndrome: 2019 update on diagnosis, risk-stratification, and management. *Am J Hematol.* (2019) 94:812–27. doi: 10.1002/ajh.25495

29. Dispenzieri A. POEMS syndrome: 2021 update on diagnosis, risk-stratification, and management. *Am J Hematol.* (2021) 96:872–88. doi: 10.1002/ajh.26240

30. Critchley WR, Fearnley GWF, Abdul-Zani I, Molina-Paris C, Bendtsen C, Zachary IC, et al. Monitoring VEGF-stimulated calcium ion flux in endothelial cells. *Methods Mol Biol.* (2022) 2475:113–24. doi: 10.1007/978-1-0716-2217-9_7

31. Hamdollah Zadeh MA, Glass CA, Magnussen A, Hancox JC, Bates DO. VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. *Microcirculation.* (2008) 15:605–14. doi: 10.1080/10739680802220323

32. Phoenix KN, Yue Z, Yue L, Cronin CG, Liang BT, Hoeppner LH, et al. PLCbeta2 promotes VEGF-induced vascular permeability. *Arterioscler Thromb Vasc Biol.* (2022) 42:1229–41. doi: 10.1161/ATVBAHA.122.317645

33. Derricks KE, Trinkaus-Randall V, Nugent MA. Extracellular matrix stiffness modulates VEGF calcium signaling in endothelial cells: individual cell and population analysis. *Integr Biol.* (2015) 7:1011–25. doi: 10.1039/C5IB00140D

34. Pan Q, Li J, Li F, Zhou D, Zhu Z. Characterizing POEMS syndrome with 18F-FDG PET/CT. *J Nucl Med.* (2015) 56:1334–7. doi: 10.2967/jnumed.115.160507

35. Li J, Zhou DB, Huang Z, Jiao L, Duan MH, Zhang W, et al. Clinical characteristics and long-term outcome of patients with POEMS syndrome in China. *Ann Hematol.* (2011) 90:819–26. doi: 10.1007/s00277-010-1149-0

36. Waner T, Nyska A. The toxicological significance of decreased activities of blood alanine and aspartate aminotransferase. *Vet Res Commun.* (1991) 15:73–8. doi: 10.1007/BF00497793

37. Ye W, Wang C, Cai QQ, Cai H, Duan MH Li H, et al. Renal impairment in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome: incidence, treatment and outcome. *Nephrol Dial Transplant.* (2016) 31:275–83.

38. Tsuda S, Nakayama M, Matsukuma Y, Yoshitomi R, Haruyama N, Fukui A, et al. Subclinical hypothyroidism is independently associated with poor renal outcomes in patients with chronic kidney disease. *Endocrine.* (2021) 73:141–50. doi: 10.1007/s12020-021-02611-6

39. Bulur O, Dal K, Ertugrul DT, Eser M, Kaplan Efe F, Karakaya S, et al. Renal function improves with the treatment of hypothyroidism. *Endocr Res.* (2017) 42:246–51. doi: 10.1080/07435800.2017.1293686

40. Tian Y, Liu M, Sun Y, Fu S. When liver disease diagnosis encounters deep learning: analysis, challenges, and prospects. *iLiver.* (2023) 2:73–87. doi: 10.1016/j.iliver.2023.02.002